Zobrazeno 1 - 10
of 78
pro vyhledávání: '"AKO HOSONO"'
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12095-12105 (2023)
Abstract Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of
Externí odkaz:
https://doaj.org/article/c0255b117bae403e9d5e854df13ba152
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Michiyo Mizuno, Ikuko Chiba, Toru Mukohara, Miki Kondo, Kazushi Maruo, Tomohiro Ohigashi, Miki Naruo, Yoshihiro Asano, Tatsuya Onishi, Hiroshi Tanabe, Rieko Muta, Saori Mishima, Susumu Okano, Masami Yuda, Ako Hosono, Yuri Ueda, Hiroko Bando, Hiroya Itagaki, Carol Estwing Ferrans, Tetsuo Akimoto
Publikováno v:
Contemporary Clinical Trials Communications, Vol 30, Iss , Pp 101035- (2022)
Background: The aim of the trial is to evaluate the effectiveness of interventions provided by online support program apps, adopting health-related quality of life (HR-QOL) scores as indicators. Methods: The design is as an open, randomized, parallel
Externí odkaz:
https://doaj.org/article/f42c280edfd14d53b2fc8ca342384431
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Yoko Fukasawa, Kanako Mamishin, Ayumi Komuro, Mashiro Okunaka, Chihiro Kondoh, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Breast, Vol 58, Iss , Pp 50-56 (2021)
Background: Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy. Although weekly paclitaxel plus bevacizumab (wPTX + BV) achieves a high response rate in human epidermal growt
Externí odkaz:
https://doaj.org/article/1ee0cb78f98046edb5ecc170618af845
Autor:
Katsutsugu Umeda, Takako Miyamura, Kenji Yamada, Hideki Sano, Ako Hosono, Minako Sumi, Hajime Okita, Tadashi Kumamoto, Akira Kawai, Junya Hirayama, Ryoji Jyoko, Akihisa Sawada, Hideki Nakayama, Yosuke Hosoya, Naoko Maeda, Nobuyuki Yamamoto, Chihaya Imai, Daiichiro Hasegawa, Motoaki Chin, Toshifumi Ozaki, Japan Ewing Sarcoma Study Group
Publikováno v:
Cancer Reports, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Background Patients with Ewing's sarcoma family of tumors (ESFT) who experience relapse or progression have a poor prognosis. Aim This study aimed to identify the prognostic and therapeutic factors affecting overall survival (OS) of patients
Externí odkaz:
https://doaj.org/article/5b28cd8c51df492eb6a55cbd606ac23f
Autor:
Akinori Sasaki, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Hirofumi Mukai, Takayuki Yoshino, Toru Mukohara
Publikováno v:
Case Reports in Oncological Medicine, Vol 2020 (2020)
Intestinal perforation is a rare adverse event of antineoplastic therapy. However, once it occurs, it is potentially fatal. This report describes a case of intestinal perforation caused by bevacizumab in a patient with ovarian cancer who concurrently
Externí odkaz:
https://doaj.org/article/40a090c3de0143138e39a456c396b54e
Autor:
Nobuhiro Tsuchiya, Ako Hosono, Toshiaki Yoshikawa, Kayoko Shoda, Kazuto Nosaka, Manami Shimomura, Junichi Hara, Chika Nitani, Atsushi Manabe, Hiroki Yoshihara, Yosuke Hosoya, Hide Kaneda, Yoshiaki Kinoshita, Kenichi Kohashi, Kenichi Yoshimura, Norihiro Fujinami, Keigo Saito, Shoichi Mizuno, Tetsuya Nakatsura
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3-peptid
Externí odkaz:
https://doaj.org/article/5f76819309494872a07ab5ff75f4dada
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Hiromichi Nakajima, Megumi Kawamoto, Kaede Baba, Kanako Mamishin, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Tomoaki Sasaki, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Japanese Journal of Clinical Oncology. 53:105-114
Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the standard treatment for advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a rare (1–3.3%) but serious adverse event associated with CDK4/6 inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1104059874437cc3479bc7074f648fcc
https://doi.org/10.1093/jjco/hyac168
https://doi.org/10.1093/jjco/hyac168
Autor:
Mao Uematsu, Hiromichi Nakajima, Ako Hosono, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Tetsuo Akimoto, Toru Mukohara
Publikováno v:
Melanoma Research; Dec2023, Vol. 33 Issue 6, p547-552, 6p
Autor:
Yoko Fukasawa, Nobuaki Matsubara, Chihiro Kondoh, Takehiro Nakao, Shota Kusuhara, Katsuya Tsuchihara, Takeshi Kuwata, Akiko Nakayama, Ako Hosono, Chikako Funasaka, Yoichi Naito, Sachiyo Mimaki, Toru Mukohara, Kenichi Harano
Publikováno v:
Oncologist
Somatic mutations in human epidermal growth factor receptor 2 (HER2) are present in approximately 3% of breast cancers. Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d859355c23eac21b8a380da2ace89a8
https://doi.org/10.1002/onco.13715
https://doi.org/10.1002/onco.13715